Cargando…

Angiotensin-I-converting enzyme inhibitory peptides in milk fermented by indigenous lactic acid bacteria

BACKGROUND AND AIM: Fermented milk can be used to produce antihypertensive peptides. Lactic acid bacteria (LAB) with its proteolytic system hydrolyze milk protein during fermentation to produce several peptides, which include antihypertensive bioactive peptides. This study aimed to investigate the a...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubak, Yuliana Tandi, Nuraida, Lilis, Iswantini, Dyah, Prangdimurti, Endang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Veterinary World 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096298/
https://www.ncbi.nlm.nih.gov/pubmed/32255978
http://dx.doi.org/10.14202/vetworld.2020.345-353
_version_ 1783510775319494656
author Rubak, Yuliana Tandi
Nuraida, Lilis
Iswantini, Dyah
Prangdimurti, Endang
author_facet Rubak, Yuliana Tandi
Nuraida, Lilis
Iswantini, Dyah
Prangdimurti, Endang
author_sort Rubak, Yuliana Tandi
collection PubMed
description BACKGROUND AND AIM: Fermented milk can be used to produce antihypertensive peptides. Lactic acid bacteria (LAB) with its proteolytic system hydrolyze milk protein during fermentation to produce several peptides, which include antihypertensive bioactive peptides. This study aimed to investigate the ability of indigenous LAB for the production of angiotensin-I-converting enzyme inhibitory (ACE-I) peptides in fermented milk and to characterize the ACEI peptides. MATERIALS AND METHODS: Reconstituted milk (11%) inoculated with ten LAB isolates, and then incubated at 37°C until it reaches pH 4.6. The evaluation was carried out for LAB count, lactic acid concentration, peptide content, and ACE-I activity. The low molecular weight (MW) peptides (<3 kDa) were identified using Nano LC Ultimate 3000 series system Tandem Q Exactive Plus Orbitrap high-resolution mass spectrometry. RESULTS: The result showed that the ten LAB isolates were able to produce ACE-I in fermented milk with the activities in the range of 22.78±2.55-57.36±5.40%. The activity of ACE-I above 50% produced by Lactobacillus delbrueckii BD7, Lactococcus lactis ssp. lactis BD17, and Lactobacillus kefiri YK4 and JK17, with the highest activity of ACE-I produced by L. kefiri YK4 (IC(50) 0.261 mg/mL) and L. kefiri JK17 (IC(50) 0.308 mg/mL). Results of peptide identification showed that L. kefiri YK 4 could release as many as 1329, while L. kefiri JK 17 could release 174 peptides. The peptides produced were 95% derived from casein. The other peptides were from ά-lactalbumin, β-lactoglobulin, and serum amyloid A. The peptides produced consisted of 6-19 amino acid residues, with MWs of 634-2079 Dalton and detected at 317-1093 m/z. A total of 30 peptides have been recognized based on literature searches as ACE-I peptides (sequence similarity: 100%). CONCLUSION: L. kefiri YK4 and JK17 are the potential to be used as starter cultures to produce the bioactive peptide as ACE-I in fermented milk.
format Online
Article
Text
id pubmed-7096298
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Veterinary World
record_format MEDLINE/PubMed
spelling pubmed-70962982020-04-01 Angiotensin-I-converting enzyme inhibitory peptides in milk fermented by indigenous lactic acid bacteria Rubak, Yuliana Tandi Nuraida, Lilis Iswantini, Dyah Prangdimurti, Endang Vet World Research Article BACKGROUND AND AIM: Fermented milk can be used to produce antihypertensive peptides. Lactic acid bacteria (LAB) with its proteolytic system hydrolyze milk protein during fermentation to produce several peptides, which include antihypertensive bioactive peptides. This study aimed to investigate the ability of indigenous LAB for the production of angiotensin-I-converting enzyme inhibitory (ACE-I) peptides in fermented milk and to characterize the ACEI peptides. MATERIALS AND METHODS: Reconstituted milk (11%) inoculated with ten LAB isolates, and then incubated at 37°C until it reaches pH 4.6. The evaluation was carried out for LAB count, lactic acid concentration, peptide content, and ACE-I activity. The low molecular weight (MW) peptides (<3 kDa) were identified using Nano LC Ultimate 3000 series system Tandem Q Exactive Plus Orbitrap high-resolution mass spectrometry. RESULTS: The result showed that the ten LAB isolates were able to produce ACE-I in fermented milk with the activities in the range of 22.78±2.55-57.36±5.40%. The activity of ACE-I above 50% produced by Lactobacillus delbrueckii BD7, Lactococcus lactis ssp. lactis BD17, and Lactobacillus kefiri YK4 and JK17, with the highest activity of ACE-I produced by L. kefiri YK4 (IC(50) 0.261 mg/mL) and L. kefiri JK17 (IC(50) 0.308 mg/mL). Results of peptide identification showed that L. kefiri YK 4 could release as many as 1329, while L. kefiri JK 17 could release 174 peptides. The peptides produced were 95% derived from casein. The other peptides were from ά-lactalbumin, β-lactoglobulin, and serum amyloid A. The peptides produced consisted of 6-19 amino acid residues, with MWs of 634-2079 Dalton and detected at 317-1093 m/z. A total of 30 peptides have been recognized based on literature searches as ACE-I peptides (sequence similarity: 100%). CONCLUSION: L. kefiri YK4 and JK17 are the potential to be used as starter cultures to produce the bioactive peptide as ACE-I in fermented milk. Veterinary World 2020-02 2020-02-21 /pmc/articles/PMC7096298/ /pubmed/32255978 http://dx.doi.org/10.14202/vetworld.2020.345-353 Text en Copyright: © Rubak, et al. http://creativecommons.org/licenses/by/4.0 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Rubak, Yuliana Tandi
Nuraida, Lilis
Iswantini, Dyah
Prangdimurti, Endang
Angiotensin-I-converting enzyme inhibitory peptides in milk fermented by indigenous lactic acid bacteria
title Angiotensin-I-converting enzyme inhibitory peptides in milk fermented by indigenous lactic acid bacteria
title_full Angiotensin-I-converting enzyme inhibitory peptides in milk fermented by indigenous lactic acid bacteria
title_fullStr Angiotensin-I-converting enzyme inhibitory peptides in milk fermented by indigenous lactic acid bacteria
title_full_unstemmed Angiotensin-I-converting enzyme inhibitory peptides in milk fermented by indigenous lactic acid bacteria
title_short Angiotensin-I-converting enzyme inhibitory peptides in milk fermented by indigenous lactic acid bacteria
title_sort angiotensin-i-converting enzyme inhibitory peptides in milk fermented by indigenous lactic acid bacteria
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096298/
https://www.ncbi.nlm.nih.gov/pubmed/32255978
http://dx.doi.org/10.14202/vetworld.2020.345-353
work_keys_str_mv AT rubakyulianatandi angiotensiniconvertingenzymeinhibitorypeptidesinmilkfermentedbyindigenouslacticacidbacteria
AT nuraidalilis angiotensiniconvertingenzymeinhibitorypeptidesinmilkfermentedbyindigenouslacticacidbacteria
AT iswantinidyah angiotensiniconvertingenzymeinhibitorypeptidesinmilkfermentedbyindigenouslacticacidbacteria
AT prangdimurtiendang angiotensiniconvertingenzymeinhibitorypeptidesinmilkfermentedbyindigenouslacticacidbacteria